Baran Anna, Kiluk Paulina, Świderska Magdalena, Maciaszek Magdalena, Myśliwiec Hanna, Flisiak Iwona
Department of Dermatology and Venereology Medical University of Bialystok, 15-540 Bialystok, Zurawia 14 St, Poland.
Department of Physiology, Medical University of Bialystok, 15-222 Bialystok, Mickiewicza 2C St, Poland.
Lipids. 2019 Aug;54(8):445-452. doi: 10.1002/lipd.12173. Epub 2019 Jul 8.
Psoriasis is a systemic disease associated with metabolic syndrome and cardiometabolic diseases. Adipocyte fatty acid-binding protein (A-FABP, FABP4) is a relevant mediator of lipid metabolism and several comorbidities development. Aim of the study was to explore the possible role of FABP4 in psoriasis and assess its relationship with disease activity, inflammation or metabolic disturbances, and impact of systemic treatment. Fasting blood samples were obtained from 33 patients with active plaque-type psoriasis before and after 12 weeks of therapy and from 11 healthy volunteers. Serum FABP4 concentrations were analyzed by the enzyme-linked immunosorbent assay (ELISA) and statistically analyzed for their correlations with clinical outcomes and the treatment introduced. Serum FABP4 levels were significantly increased in psoriatics compared to controls (p = 0.03). No relationship between the protein and psoriasis severity expressed through psoriasis area and severity index (PASI) was noted (p = 0.57). FABP4 did not correlate with CRP (p = 0.41), lipid profile, and body mass index (BMI) nor the glucose level or liver enzyme activity. FABP4 significantly correlated with morphotic blood elements. After total therapy, FABP4 did not statistically change (p = 0.07), but significantly decreased after administering acitretin (p = 0.03). FABP4 is a potential marker of psoriasis and clinical outcome after therapy with acitretin. Adipocyte-type FABP may be related to hematological disorders or obesity-mediated comorbidities in psoriasis.
银屑病是一种与代谢综合征和心脏代谢疾病相关的全身性疾病。脂肪细胞脂肪酸结合蛋白（A-FABP，FABP4）是脂质代谢和几种合并症发展的相关介质。本研究的目的是探讨FABP4在银屑病中的可能作用，并评估其与疾病活动、炎症或代谢紊乱的关系以及全身治疗的影响。在治疗12周前后，从33例活动性斑块型银屑病患者以及11名健康志愿者中采集空腹血样。通过酶联免疫吸附测定（ELISA）分析血清FABP4浓度，并对其与临床结果和所采用治疗方法的相关性进行统计学分析。与对照组相比，银屑病患者的血清FABP4水平显著升高（p = 0.03）。未发现该蛋白与通过银屑病面积和严重程度指数（PASI）表示的银屑病严重程度之间存在相关性（p = 0.57）。FABP4与CRP（p = 0.41）、血脂谱、体重指数（BMI）、血糖水平或肝酶活性均无相关性。FABP4与变形血细胞显著相关。在整个治疗后，FABP4没有统计学上的变化（p = 0.07），但在服用阿维A后显著下降（p = 0.03）。FABP4是银屑病的潜在标志物以及阿维A治疗后的临床结果。脂肪细胞型FABP可能与银屑病中的血液系统疾病或肥胖介导的合并症有关。
